CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia
Conditions: Blasts 5 Percent or More of Bone Marrow Nucleated Cells; Recurrent Acute Myeloid Leukemia Interventions: Drug: Gemtuzumab Ozogamicin; Drug: Liposome-encapsulated Daunorubicin-Cytarabine Sponsors: Jonsson Comprehensive Cancer Center; National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials